Introduction
============

Lung cancer remains the most frequent cause of cancer-related death in developed countries, and an estimated 1.8 million new cases of lung cancer occurred in 2012 ([@b1-ijo-48-02-0450]). Approximately 80% of lung cancers are classified histopathologically as non-small cell lung cancer (NSCLC), and NSCLC are subdivided into four major histological subtypes: adenocarcinoma, squamous cell carcinoma (SCC), large cell carcinoma, and neuroendocrine cancer ([@b2-ijo-48-02-0450]). NSCLC, as compared to small cell lung cancer, is less sensitive to anticancer drugs and radiation therapy. Recently, molecular target therapies for adenocarcinoma (gefitinib, erlotinib and crizotinib) have shown remarkable therapeutic efficacy; however, no targeted therapeutics are currently approved for treatment of lung SCC ([@b3-ijo-48-02-0450]). Therefore, the lung squamous cell carcinomas need a new treatment option.

The human genome sequence era and the discovery of microRNAs (miRNAs) in human genomes have brought great changes to the study of human cancers. miRNAs are endogenous small non-coding RNA molecules (19--22 bases in length) that regulate protein-coding gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner ([@b4-ijo-48-02-0450],[@b5-ijo-48-02-0450]). Substantial evidence suggests that miRNAs are aberrantly expressed in many human cancers and play significant roles in human oncogenesis and metastasis ([@b6-ijo-48-02-0450],[@b7-ijo-48-02-0450]). The nature of miRNAs is unique in that one miRNA has the ability to regulate multiple protein-coding RNAs. Bioinformatic predictions indicate that miRNAs regulate 30--60% of the protein-coding genes in the human genome ([@b5-ijo-48-02-0450],[@b6-ijo-48-02-0450]). Therefore, identification of tumor-suppressive or oncogenic miRNAs and the miRNAs-mediated novel cancer networks are the first step toward elucidating the molecular mechanisms of human cancers.

Based on this foregoing discussion, we sequentially identified tumor-suppressive miRNAs and the miRNA-regulated oncogenic genes in various types of cancers ([@b8-ijo-48-02-0450]--[@b11-ijo-48-02-0450]). A recent study of lung SCC showed that *miRNA-1/133a*-clustered miRNAs inhibit cancer cell migration and invasion by targeting the CORO1C gene encoding a member of the WD repeat protein family and is involved in a variety of cellular processes ([@b12-ijo-48-02-0450]). Moreover, tumor-suppressive *miR-206* inhibited dual signaling networks activated by MET and EGFR in lung SCC cells ([@b13-ijo-48-02-0450]).

Our miRNA expression signatures of human cancers demonstrated that the miR-29 family (*miR-29a*, *miR-29b*, and *miR-29c*) was downregulated in cancer tissues compared to normal tissues ([@b8-ijo-48-02-0450],[@b9-ijo-48-02-0450],[@b14-ijo-48-02-0450]--[@b17-ijo-48-02-0450]), suggesting that these miRNAs function as tumor suppressors in lung SCC cells. However, *miR-29s*-regulating molecular networks have not been sufficiently analyzed in this disease. The aim of this study is to investigate the functional significance of *miR-29s* in lung SCC and to identify *miR-29s*-regulating molecular targets in lung SCC cells.

In this study, we found that the restoration of all *miR-29s* inhibited cancer cell migration and invasion, directly targeting the lysyl oxidase-like 2 (*LOXL2*) gene. Moreover, overexpression of LOXL2 was detected in lung SCC clinical specimens, and silencing of *LOXL2* significantly inhibited cell migration and invasion by cancer cells. The tumor-suppressive *miR-29*-*LOXL2* axis may provide new insights into the potential mechanisms of lung SCC oncogenesis and metastasis.

Materials and methods
=====================

Clinical specimens and RNA extraction
-------------------------------------

A total of 32 lung SCCs and 22 normal lung specimens were collected from patients who underwent pneumonectomy at Kagoshima University Hospital from 2010 to 2013. The patient backgrounds and clinical characteristics are summarized in [Table I](#tI-ijo-48-02-0450){ref-type="table"}. Archival formalin-fixed paraffin-embedded (FFPE) samples were used for qRT-PCR analysis and immunohistochemistry.

Samples were staged according to the International Association for the Study of Lung Cancer TNM classification, and they were histologically graded ([@b18-ijo-48-02-0450]). This study was approved by the Institutional Review Board for Clinical Research of Kagoshima University School of Medicine. Prior written informed consent and approval were provided by each patient.

FFPE tissues were sectioned to a thickness of 10 μm, and 8 tissue sections were used for RNA extraction. Total RNA (including miRNA) was extracted using Recover All™ Total Nucleic Acid Isolation kit (Ambion, Austin, TX, USA) using the manufacturer\'s protocol. The integrity of the RNA was checked with an RNA 6000 Nano assay kit and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

Cell culture and RNA extraction
-------------------------------

We used human lung SCC cell lines (EBC-1 and SK-MES-1) obtained from the Japanese Cancer Research Resources Bank (JCRB) and the American Type Culture Collection (Manassas, VA, USA), respectively. Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and maintained in a humidified incubator (5% CO~2~) at 37°C.

Total RNA was isolated using Isogen (Nippon Gene, Tokyo, Japan) according to the manufacturer\'s protocol. The integrity of the RNA was checked with an RNA 6000 Nano assay kit and a 2100 Bioanalyzer (Agilent Technologies).

Quantitative reverse transcription PCR (qRT-PCR)
------------------------------------------------

The procedure for PCR quantification was described previously ([@b9-ijo-48-02-0450]--[@b11-ijo-48-02-0450]). TaqMan probes and primers for *LOXL2* (P/N: Hs00158757_m1; Applied Biosystems, Foster City, CA, USA) were assay-on-demand gene expression products. Stem-loop RT-PCRs for *miR-29a* (P/N: 002112; Applied Biosystems), *miR-29b* (P/N: 000413), and *miR-29c* (P/N: 000587) were used to quantify the expression levels of miRNAs according to the manufacturer\'s protocol. To normalize the data for quantification of mRNA and miRNAs, we used human *GUSB* (P/N: Hs99999908_m1; Applied Biosystems) and *RNU48* (P/N: 001006; Applied Biosystems), respectively.

Transfections with mature miRNA and small interfering RNA (siRNA) into cell lines
---------------------------------------------------------------------------------

The following mature miRNA species were used in the present study: Pre-miR™ miRNA precursors (hsa-*miR-29a-3p*, P/N: AM 12499; hsa-*miR-29b-3p*, P/N: AM 10103; hsa-*miR-29c-3p*, P/N: AM 10518; and negative control miRNA, P/N: AM 17111), Stealth Select RNAi siRNA, *si-LOXL2* (P/N: HSS106124, P/N: HSS106125 and P/N: HSS180848; Invitrogen, Carlsbad, CA, USA), and negative-control siRNA (D-001810-10; Thermo Fisher Scientific, Waltham, MA, USA). RNAs were incubated with OPTI-MEM and Lipofectamine RNAiMAX Reagent (both from Invitrogen) as described previously ([@b9-ijo-48-02-0450]--[@b11-ijo-48-02-0450]).

Cell proliferation, migration, and invasion assays
--------------------------------------------------

Cells were transfected with 10 nM miRNAs by reverse transfection and plated in 96-well plates at 8×10^3^ cells/well. After 96 h, cell proliferation was determined with the XTT assay using the Cell Proliferation kit II (Roche Molecular Biochemicals, Mannheim, Germany) as described previously ([@b9-ijo-48-02-0450]--[@b11-ijo-48-02-0450]).

Cell migration activity was evaluated with wound healing assays. Cells were plated in 6-well plates at 8×10^5^ cells/well, and after 48 h of transfection, the cell monolayer was scraped using a P-20 micropipette tip. The initial gap length (0 h) and the residual gap length 24 h after wounding were calculated from photomicrographs as described previously ([@b9-ijo-48-02-0450]--[@b11-ijo-48-02-0450]).

Cell invasion assays were performed using modified Boyden chambers, consisting of Transwell-precoated Matrigel membrane filter inserts with 8 μm pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA). After 72 h of transfection, cells were plated in 24-well plates at 1×10^5^ cells/well. Minimum essential medium containing 10% FBS in the lower chamber served as the chemoattractant, as described previously ([@b9-ijo-48-02-0450]--[@b11-ijo-48-02-0450]). All experiments were performed in triplicate.

Western blotting
----------------

After 96 h of transfection, protein lysates (50 μg) were separated on NuPAGE on 4--12% Bis-Tris gels (Invitrogen) and transferred to polyvinylidene fluoride membranes. Immunoblotting was performed with diluted anti-LOXL2 antibodies (1:1,000; ab96233; Abcam, Cambridge, UK) and anti-GAPDH antibodies (1:5,000; MAB374; Chemicon, Temecula, CA, USA). The membrane was washed and then incubated with an anti-rabbit-IgG, HRP-linked antibody (\#7074; Cell Signaling Technology, Danvers, MA, USA). Specific complexes were visualized with an echochemiluminescence (ECL) detection system (GE Healthcare, Little Chalfont, UK) as described previously ([@b9-ijo-48-02-0450]--[@b11-ijo-48-02-0450]).

Plasmid construction and dual-luciferase reporter assay
-------------------------------------------------------

A partial wild-type sequence of the *LOXL2* 3′-UTR or those with a deleted *miR-29* target site (position 555--561 or position 757--763 of the *LOXL2* 3′-UTR) was inserted between the *Xho*I-*Pme*I restriction sites in the 3′-UTR of the hRluc gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA).

The synthesized DNA was cloned into the psiCHECK-2 vector. EBC-1 cells and SK-MES-1 cells were transfected with a 50 ng vector, 10 nM miRNAs, and 1 μl of Lipofectamine 2000 in 100 μl of Opti-MEM (both from Invitrogen). The activities of Firefly and *Renilla* luciferases in cell lysates were determined with a dual-luciferase assay system (E1910; Promega). Normalized data were calculated as the quotient of *Renilla*/Firefly luciferase activities.

Immunohistochemistry
--------------------

We stained the tissue array (LC2083; US Biomax, Rockville, MD, USA). The tissues were immunostained following the manufacturer\'s protocol with an UltraVision Detection System (Thermo Fisher Scientific). The primary rabbit polyclonal antibodies against LOXL2 (ab96233) were diluted 1:1,000. The slides were treated with biotinylated goat anti-rabbit antibodies. Diaminobenzidine hydrogen peroxidase was the chromogen, and counterstaining was done with 0.5% hematoxylin.

Identification of putative miR-29 target genes
----------------------------------------------

To identify putative *miR-29*-regulated genes, we used the TargetScan database (<http://www.targetscan.org/>). We investigated the expression status of putative targets of *miR-29* using lung SCC clinical expression data from the GEO database (accession no. GSE 11117). Additionally, we performed gene expression analysis using *miR-29a* transfected EBC-1 cells. Oligo-microarray procedures and data mining methods were described in previous studies ([@b9-ijo-48-02-0450],[@b10-ijo-48-02-0450]).

Statistical analysis
--------------------

Relationships between two or three variables and numerical values were analyzed using the Mann-Whitney U test or Bonferroni-adjusted Mann-Whitney U test. Expert StatView version 4 was used in these analyses.

Results
=======

Expression levels of miR-29a, miR-29b and miR-29c in lung SCC clinical specimens
--------------------------------------------------------------------------------

The expression levels of *miR-29a*, *miR-29b* and *miR-29c* were significantly reduced in tumor tissues compared to corresponding noncancerous tissues (P\<0.0001, P=0.0031 and P\<0.0001, respectively) ([Fig. 1A--C](#f1-ijo-48-02-0450){ref-type="fig"}). Spearman\'s rank test showed a positive correlation between the expression of *miR-29a* and that of *miR-29b* (R=0.836 and P\<0.0001) ([Fig. 1D](#f1-ijo-48-02-0450){ref-type="fig"}). The expression of *miR-29a* was positively correlated with that of *miR-29c* (R=0.878 and P\<0.0001) ([Fig. 1E](#f1-ijo-48-02-0450){ref-type="fig"}). Similarly, the expression of *miR-29b* was positively correlated with that of *miR-29c* (R=0.744 and P\<0.0001) ([Fig. 1F](#f1-ijo-48-02-0450){ref-type="fig"}).

Effects of miR-29a, miR-29b and miR-29c restoration on the proliferation, migration and invasion in lung SCC cell lines
-----------------------------------------------------------------------------------------------------------------------

To examine the functional roles of the *miR-29* family (*miR-29a*, *miR-29b* and *miR-29c*), we performed gain-of-function studies using miRNA transfection into lung SCC cell lines (EBC-1 and SK-MES-1).

XTT assays revealed significant inhibition of cell proliferation in SK-MES-1 cells transfected with *miR-29s* in comparison with mock or control transfectants (P\<0.0001) ([Fig. 2A](#f2-ijo-48-02-0450){ref-type="fig"}). Otherwise, in EBC-1 cells transfected with *miR-29s*, there was no significant inhibition of cell proliferation in comparison with control transfectants ([Fig. 2A](#f2-ijo-48-02-0450){ref-type="fig"}).

Wound healing assays showed significant inhibition of cell migration activity after transfection with *miR-29s* (P\<0.0001) ([Fig. 2B](#f2-ijo-48-02-0450){ref-type="fig"}).

Similarly, Matrigel invasion assays revealed that transfection with *miR-29* reduced cell invasion activities (P\<0.0001) ([Fig. 2C](#f2-ijo-48-02-0450){ref-type="fig"}).

Identification of candidate target genes of miR-29s in lung SCC
---------------------------------------------------------------

To identify molecular targets of *miR-29s*, we used a combination of *in silico* analysis and lung SCC gene expression data. In total, 2,627 genes were putative targets of *miR-29s* according to the TargetScan database. Next, we pared down the list of genes based on two kinds of gene expression data: downregulated genes (Log~2~ ratio \<-2.0) following *miR-29a*-transfected EBC-1 cells and upregulated genes determined by the gene expression data set of lung SCC clinical specimens according to the GEO database (accession no. GSE 11117). From this selection, 7 candidate genes were identified as targets of the *miR-29s* ([Table II](#tII-ijo-48-02-0450){ref-type="table"}). Among these genes, we focused on the *LOXL2* gene and examined the *LOXL2* function and characteristics in further analyses. Our strategy for selecting *miR-29* target genes is shown in [Fig. 3](#f3-ijo-48-02-0450){ref-type="fig"}.

LOXL2 is directly regulated by miR-29s in lung SCC cells
--------------------------------------------------------

We performed qRT-PCR and western blotting to confirm LOXL2 downregulation following restoration of *miR-29s* expression in lung SCC cell lines. The mRNA and protein expression levels of LOXL2 were significantly repressed in *miR-29s* transfectants in comparison with mock or miR-control transfectants (P\<0.001) ([Fig. 4](#f4-ijo-48-02-0450){ref-type="fig"}).

The TargetScan database identified two putative target sites in the 3′-UTR of *LOXL2* ([Fig. 5](#f5-ijo-48-02-0450){ref-type="fig"}, upper part). A lucif-erase reporter assay confirmed that the 3′-UTR of *LOXL2* was indeed an actual target of *miR-29s*. Luciferase activity was significantly decreased in two miR-29 target sites (positions 555--561 and 757--763 in the 3′-UTR of *LOXL2*) ([Fig. 5](#f5-ijo-48-02-0450){ref-type="fig"}, lower part).

Effects of downregulating LOXL2 on cell proliferation, migration, and invasion in lung SCC cell lines
-----------------------------------------------------------------------------------------------------

To investigate the functional role of *LOXL2* in lung SCC cells, we performed loss-of-function studies using *si-LOXL2* transfectants. First, we evaluated the knockdown efficiency of *si-LOXL2* transfection in lung SCC cells. Western blotting and qRT-PCR indicated that *si-LOXL2* effectively downregulated *LOXL2* expression in lung SCC cells (P\<0.0001) ([Fig. 6](#f6-ijo-48-02-0450){ref-type="fig"}).

XTT assays demonstrated that cell proliferation was not inhibited in *si-LOXL2* transfectants in comparison with mock or si-control transfectants in lung SCC cells ([Fig. 7A](#f7-ijo-48-02-0450){ref-type="fig"}).

Wound healing assays showed significant inhibition of cell migration in *si-LOXL2* transfectants in comparison with mock or si-control transfectants in lung SCC cells (P\<0.0001) ([Fig. 7B](#f7-ijo-48-02-0450){ref-type="fig"}).

Similarly, Matrigel invasion assays revealed that the number of invading cells was significantly decreased when lung SCC cells were transfected with *si-LOXL2* (P\<0.0001) ([Fig. 7C](#f7-ijo-48-02-0450){ref-type="fig"}).

Immunohistochemical staining of LOXL2 in lung SCC clinical specimens
--------------------------------------------------------------------

We confirmed the expression status of *LOXL2* in lung SCC clinical specimens using immunohistochemical staining. Fifty specimens were checked in this study: 32 of 40 lung SCC specimens stained moderately or strongly, and 9 of 10 normal lung specimens stained weakly or negatively for *LOXL2* ([Table III](#tIII-ijo-48-02-0450){ref-type="table"} and [Fig. 8](#f8-ijo-48-02-0450){ref-type="fig"}).

Discussion
==========

Recent studies have suggested that the interaction of cancer cells with their microenvironment has influenced the initiation, development, and metastasis of tumors ([@b19-ijo-48-02-0450],[@b20-ijo-48-02-0450]). Overexpression of extracellular matrix (ECM) components has frequently been observed in cancer lesions and aberrantly expressed ECM-mediated signals have triggered cancer cell metastasis ([@b21-ijo-48-02-0450],[@b22-ijo-48-02-0450]). Our past studies demonstrated that *miR-29s* and *miR-218* directly regulated laminin-integrin signaling and thereby activated cancer cell migration and invasion ([@b23-ijo-48-02-0450]--[@b25-ijo-48-02-0450]). Other studies indicated that *miR-29s* modulated ECM components such as collagen, laminin and elastin ([@b26-ijo-48-02-0450]). Therefore, the identification of ECM-regulated tumor-suppressive miRNAs may provide a better appreciation of novel pathways and how their interrelations are involved in cancer metastasis.

Our present data showed that all members of the *miR-29* family were significantly reduced in lung SCC specimens. Our previous studies also showed the downregulation of *miR-29s* in renal cell carcinoma, cervical cell carcinoma, and head and neck squamous cell carcinoma ([@b24-ijo-48-02-0450],[@b25-ijo-48-02-0450],[@b27-ijo-48-02-0450],[@b28-ijo-48-02-0450]) and are consistent with present data on lung SCC. However, the molecular mechanisms underlying the dysregulated expression of the *miR-29s* in lung SCC cells are still unclear. The genomic structure of the *miR-29* family consists of two clusters in the human genome: *miR-29b-1* and *miR-29a* in 7q32 and *miR-29b*-2 and *miR-29c* in 1q32 ([@b26-ijo-48-02-0450]). Several studies indicated the molecular mechanisms of the silencing of *miR-29s* ([@b26-ijo-48-02-0450]). Previous studies demonstrated that the promoter regions of *miR-29b-1*/*miR-29a* showed that two putative E-box (MYC-binding) sites, a Gli-binding site and four NF-κB-binding sites, were contained within this region, and c-Myc and NF-κB suppressed miR-29 expression at transcriptional levels ([@b29-ijo-48-02-0450]). A recent study showed that cancer cells with high *c-Myc*, low *miR-29b*, and low *FHIT* expression had a shorter overall survival and relapse-free survival in NSCLC patients ([@b30-ijo-48-02-0450]). In breast cancer, *GATA3* is a transcription factor that specifies and maintains luminal epithelial cell differentiation in the mammary gland ([@b31-ijo-48-02-0450]). Loss of GATA3 is involved in breast cancer pathogenesis ([@b31-ijo-48-02-0450]). The *miR-29a*/*miR-29b-1* promoter region contains three *GATA3*-binding sites, and *GATA3* induced *miR-29b* expression, which inhibits metastasis by targeting metastatically involved genes ([@b31-ijo-48-02-0450]). Moreover, recent data have suggested that TGF-β inhibited the expression of *miR-29s* and promoted the expression of ECM components ([@b32-ijo-48-02-0450],[@b33-ijo-48-02-0450]). However, the silencing of molecular mechanisms of *miR-29s* in lung SCC are still unclear; detailed examination will be necessary to better understand these processes.

In this study, the restoration of *miR-29s* into cancer cells significantly inhibited migration and invasion; thus *miR-29*-mediated novel targets deeply contribute to meta-static pathways. To better understand lung SCC metastasis, we searched putative *miR-29*-regulated genes by using gene expression analysis combined with *in silico* analysis. Finally, 15 putative candidate genes were listed in this analysis. Among these genes, integrin α6 (*ITGA6*) and serpin peptidase inhibitor, clade H, member 1 (*SERPINH1*) have already been reported by our group as *miR-29*-regulated genes in head and neck squamous cell carcinoma and cervical cancer ([@b24-ijo-48-02-0450],[@b28-ijo-48-02-0450]). Moreover, another group showed that *miR-29c* may be involved in the regulation of cell proliferation through targeting regulator of chromosome condensation 2 (RCC2) in gastric carcinoma ([@b34-ijo-48-02-0450]). The target gene list provided by this analysis is effective for *miR-29*-regulated target analysis.

Here, we focused on the *LOXL2* gene and validated the direct regulation of *miR-29s* in lung SCC cells. Furthermore, overexpression of LOXL2 was detected in lung SCC clinical specimens, and silencing of *LOXL2* expression in lung SCC cells inhibited cancer cell migration and invasion, indicating that *LOXL2* acts as an oncogene in the disease. Interestingly, our latest data on renal cell carcinoma also showed that *LOXL2* was a direct regulator of tumor-suppressive *miR-29s* ([@b27-ijo-48-02-0450]). The lysyl oxidase (LOX) protein family comprises LOX and four LOX-like proteins (LOXL1-LOXL4). These proteins are copper- and quinone-dependent amino oxidases ([@b35-ijo-48-02-0450]). Basically, the function of the LOX family is the covalent cross-linking of collagen and/or elastin in the ECM ([@b36-ijo-48-02-0450]--[@b38-ijo-48-02-0450]). Several studies suggested that LOXL2-mediated cancer progression cause ECM modification and increased ECM deposition, and subsequent tissue stiffness derives malignant progression through activation of ECM-integrin or ECM-growth factor signaling ([@b39-ijo-48-02-0450]--[@b42-ijo-48-02-0450]). It has been reported that overexpression of LOXL2 in a number of cancers and high expression levels of LOXL2 are correlated with cancer cell invasion, lymph node metastasis, and poor overall patient survival in patients with gastric cancer, breast cancer and squamous cell carcinomas ([@b43-ijo-48-02-0450]--[@b45-ijo-48-02-0450]).

It is well known that metastasis is associated with the aberrant activation of epithelial-mesenchymal transition (EMT)-related transcriptional factors and TGF-β signaling, which endows cancer cells with elevated capabilities to invade and disseminate to distant sites ([@b46-ijo-48-02-0450]). Previous studies have shown that LOXL2 is a direct transcriptional target of HIF1 ([@b46-ijo-48-02-0450]). Moreover, nuclear LOXL2 interacts with transcription factor SNAIL1 and represses E-cadherin as well as inducing EMT ([@b47-ijo-48-02-0450],[@b48-ijo-48-02-0450]). These findings suggest that hypoxia conditions and overexpression of LOXL2 trigger the ability for metastasis acquisition of the cancer cells. Several studies indicated that targeting LOXL2 with antibodies inhibited primary and metastatic xenograft models of cancers via suppression of SRC/FAK signaling or the production of growth factors and cytokines and TGF-β pathways ([@b49-ijo-48-02-0450],[@b50-ijo-48-02-0450]). Interestingly, recent data indicated that expression of the LOX family was induced by TGF-β ([@b51-ijo-48-02-0450],[@b52-ijo-48-02-0450]). In contrast, TGF-β inhibited the expression of *miR-29s* and promoted the expression of ECM components ([@b53-ijo-48-02-0450],[@b54-ijo-48-02-0450]). The present data suggest that the *miR-29*-*LOXL2* axis regulates the cancer cell microenvironment and activates metastatic pathways. Therefore, the *miR-29*-regulated meta-static pathway is a potential target in the development of novel therapies to treat pathological lung SCC.

In conclusion, downregulation of *miR-29s* was frequently observed in lung SCC clinical specimens, and all members of the *miR-29* family act as tumor-suppressive miRNAs in this disease. *LOXL2* was a direct regulator of *miR-29s* in lung SCC cells. Overexpression of LOXL2 was detected in lung SCC clinical specimens, and functional assays showed that *LOXL2* promoted cancer cell invasion and migration, indicating this gene as an oncogene in lung SCC cells. The identification of novel molecular pathways mediated by the *miR-29*-*LOXL2* axis may lead to a better understanding of lung SCC and the development of new therapeutic strategies to treat this disease.

![The expression levels of *miR-29a*, *miR-29b* and *miR-29c* in clinical specimens and cell lines. Real-time PCR showed that the expression levels of (A) *miR-29a*, (B) *miR-29b* and (C) *miR-29c* were significantly lower in lung SCC tissues than in normal lung tissues (P\<0.0001, P=0.0031 and P\<0.0001, respectively). *RNU48* was used as an internal control. Correlations between (D) *miR-29a-miR-29b*, (E) *miR-29b-miR-29c* and (F) *miR-29c-miR-29a* were determined in lung SCC clinical specimens.](IJO-48-02-0450-g00){#f1-ijo-48-02-0450}

![Effects of *miR-29a*, *miR-29b* and *miR-29c* transfection on SK-MES-1 and EBC-1 cells. (A) Cell proliferation was determined with XTT assays 96 h after transfection with 10 nM *miR-29s*, miR-control, or mock transfection. (B) Cell migration activity was determined by migration assay 48 h after transfection. (C) Cell invasion activity was determined by Matrigel invasion assay 72 h after transfection. ^\*^P\<0.0001.](IJO-48-02-0450-g01){#f2-ijo-48-02-0450}

![Flow chart of the strategy for identification of *miR-29* target genes. In total, 2,627 genes were putative targets of *miR-29s* according to the TargetScan database. We merged the expression analysis data of downregulated genes in *miR-29a*-transfected EBC-1 cells (Log~2~ ratio \<-2.0). Upregulated genes were determined according to the gene expression data set of lung SCC clinical specimens according to the GEO database (accession no. GSE 11117). From this selection, 7 candidate genes were identified as targets of the miR-29s.](IJO-48-02-0450-g02){#f3-ijo-48-02-0450}

![Direct regulation of *LOXL2* by *miR-29s* in SK-MES-1 and EBC-1 cells. (A) *LOXL2* mRNA expression was evaluated by qRT-PCR 72 h after transfection with *miR-29s*. *GUSB* was used as an internal control. (B) LOXL2 protein expression was evaluated by western blotting 96 h after transfection with *miR-29s*. GAPDH was used as a loading control.](IJO-48-02-0450-g03){#f4-ijo-48-02-0450}

![Direct regulation of *LOXL2* by *miR-29s* in lung SCC cells. A luciferase reporter assay using vectors encoding putative *miR-29* target sites at positions (A) 555--561 and (B) 757--763 for both wild-types and deletion types, respectively. *Renilla* luciferase values were normalized to Firefly luciferase values. ^\*^P\<0.0001.](IJO-48-02-0450-g04){#f5-ijo-48-02-0450}

![Silencing of *LOXL2* by using *si-LOXL2* in lung SCC cells. Silencing of *LOXL2* mRNA and protein expression by *si-LOXL2* transfection and the effects of the silencing of *LOXL2* on SK-MES-1 and EBC-1 cell activities. (A) *LOXL2* mRNA expression was evaluated by qRT-PCR 72 h after transfection with *miR-29s*. *GUSB* was used as an internal control. ^\*^P\<0.0001. (B) LOXL2 protein expression was evaluated by western blotting 96 h after transfection. GAPDH was used as a loading control.](IJO-48-02-0450-g05){#f6-ijo-48-02-0450}

![Effects of *si-LOXL2* transfection on lung SCC cell lines. (A) Cell proliferation was determined using XTT assays 96 h after transfection with 10 nM *si-LOXL2*, miR-control, or mock transfection. (B) Cell migration activity was determined by migration assay 48 h after transfection. (C) Cell invasion activity was determined by Matrigel invasion assay 72 h after transfection. ^\*^P\<0.0001.](IJO-48-02-0450-g06){#f7-ijo-48-02-0450}

![Immunohistochemical staining of LOXL2 in lung SCC specimens. Differences in LOXL2 expression are observed in cancer lesions and adjacent non-cancerous tissues in the same fields. Normal lung specimens stained negatively.](IJO-48-02-0450-g07){#f8-ijo-48-02-0450}

###### 

Characteristics of the lung cancer and normal lung cases.

  A, Characteristics of the lung cancer cases        
  --------------------------------------------- ---- ----------
  Total number                                  32   
  Median age (range)                            71   (50--88)
  Gender                                             
   Male                                         30   (93.7)
   Female                                       2    (6.3)
  Pathological stage                                 
   I~A~                                         4    (12.5)
   I~B~                                         8    (25.0)
   II~A~                                        4    (12.5)
   II~B~                                        5    (15.6)
   III~A~                                       8    (25.0)
   III~B~                                       1    (3.1)
   Unknown                                      2    (6.3)
  Differentiation                                    
   Well                                         8    (25.0)
   Moderately                                   19   (59.4)
   Poorly                                       3    (9.4)
   Unknown                                      2    (6.3)
  Pleural invasion                                   
   (+)                                          15   (46.9)
   (−)                                          17   (53.1)
  Venous invasion                                    
   (+)                                          16   (50.0)
   ( −)                                         16   (50.0)
  Lymphatic invasion                                 
   (+)                                          16   (50.0)
   ( −)                                         16   (50.0)
  Recurrence                                         
   (+)                                          9    (28.1)
   ( −)                                         20   (62.5)
   Unknown                                      3    (9.4)
                                                     
  B, Characteristics of the normal lung cases        
                                                     
  Normal lung                                   n    (%)
                                                     
  Total number                                  22   
  Median age (range)                            71   (50--88)
  Gender                                             
   Male                                         22   
   Female                                       0    

###### 

Downregulated genes in *miR-29a* transfectant.

  Entrez gene ID   Gene symbol   Description                                                                                          EBC-1 *miR-29* transfectant Log~2~ ratio   *miR-29a* conserved site   *miR-29a* poorly conserved site   GSE1117 fold-change
  ---------------- ------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------ -------------------------- --------------------------------- ---------------------
  4017             *LOXL2*       Lysyl oxidase-like 2                                                                                 −4.05                                      1                          1                                 2.10
  3038             *HAS3*        Hyaluronan synthase 3                                                                                −3.37                                      3                                                            4.19
  9535             *GMFG*        Glia maturation factor γ                                                                             −3.10                                      2                                                            ND
  3655             *ITGA6*       Integrin α6                                                                                          −2.62                                      1                                                            2.78
  634              *CEACAM1*     Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein)                     −2.58                                      1                          1                                 1.41
  871              *SERPINH1*    Serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 (collagen binding protein 1)   −2.57                                      1                                                            ND
  22801            *ITGA11*      Integrin α11                                                                                         −2.42                                      1                                                            1.50
  80381            *CD276*       CD276 molecule                                                                                       −2.35                                      1                                                            ND
  50848            *F11R*        F11 receptor                                                                                         −2.26                                      1                          1                                 ND
  8894             *EIF2S2*      Eukaryotic translation initiation factor 2, subunit 2β, 38 kDa                                       −2.17                                      1                          1                                 1.70
  91584            *PLXNA4*      Plexin A4                                                                                            −2.15                                      1                          1                                 ND
  55920            *RCC2*        Regulator of chromosome condensation 2                                                               −2.11                                      1                                                            ND
  9076             *CLDN1*       Claudin 1                                                                                            −2.10                                      1                                                            ND
  2118             *ETV4*        Ets variant 4                                                                                        −2.09                                      1                                                            4.84
  284119           *PTRF*        Polymerase I and transcript release factor                                                           −2.05                                      1                                                            −1.86

ND, no data.

###### 

Immunohistochemistry status and characteristics of the lung cancer and normal lung cases.

  A, Immunohistochemistry status and characteristic of the lung cancer cases                                               
  ---------------------------------------------------------------------------- ---------------------- --- --- --- -------- -------
  1                                                                            1                      3   1   0   III~A~   (++)
  2                                                                            2                      2   1   0   II~A~    (++)
  3                                                                            2                      2   0   0   I~B~     (+)
  4                                                                            2                      2   0   0   I~B~     (+++)
  5                                                                            2                      2   0   0   I~B~     (+++)
  6                                                                            2                      2   1   0   II~B~    (++)
  7                                                                            2                      3   2   0   III~A~   (+++)
  8                                                                            2                      2   0   0   I        (++)
  9                                                                            2                      2   2   0   III~A~   (+)
  10                                                                           2                      2   2   0   III~A~   (+)
  11                                                                           2                      2   2   0   III~A~   (+)
  12                                                                           2                      3   0   0   II~B~    (+)
  13                                                                           2                      1   0   0   I~A~     (+++)
  14                                                                           2                      2   0   0   I        (++)
  15                                                                           2                      2   1   0   II~B~    (++)
  16                                                                           2                      2   1   0   I~B~     (++)
  17                                                                           2                      3   1   0   III~A~   (+++)
  18                                                                           2                      2   0   0   I~B~     (++)
  19                                                                           2                      3   1   0   III~A~   (+++)
  20                                                                           2                      2   0   0   I~B~     (++)
  21                                                                           3                      2   0   0   I~B~     (+)
  22                                                                           3                      2   1   0   II       (++)
  23                                                                           3                      2   0   0   I~B~     (++)
  24                                                                           3                      2   0   0   I~B~     (++)
  25                                                                           3                      2   0   0   I~B~     (+++)
  27                                                                           3                      3   2   0   III~A~   (++)
  28                                                                           3                      2   0   0   I~B~     (+++)
  29                                                                           2                      3   1   0   III~A~   (+++)
  30                                                                           3                      3   1   0   IIIA     (++)
  31                                                                           3                      2   0   0   I~B~     (++)
  32                                                                           3                      3   1   0   III~A~   (++)
  33                                                                           3                      2   1   0   II~A~    (++)
  34                                                                           3                      1   2   0   III~A~   (++)
  35                                                                           3                      2   2   0   III~A~   (+)
  36                                                                           3                      2   0   0   I        (+)
  37                                                                                                  2   0   0   I~B~     (+++)
  38                                                                           3                      2   0   0   I~B~     (++)
  39                                                                           3                      2   0   0   I~B~     (+++)
  40                                                                           3                      1   0   0   I~A~     (+++)
  41                                                                           3                      2   0   0   I~B~     (++)
                                                                                                                           
  B, Immunohistochemistry status of normal lung cases                                                                      
                                                                                                                           
  Patient no.                                                                  Immunohistochemistry                        
                                                                                                                           
  111                                                                          (+)                                         
  112                                                                          (+)                                         
  113                                                                          (−)                                         
  114                                                                          (++)                                        
  115                                                                          (−)                                         
  116                                                                          (+)                                         
  117                                                                          (+)                                         
  118                                                                          (−)                                         
  119                                                                          (−)                                         
  120                                                                          (−)                                         
